Screener
TG Therapeutics TGTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's retained earnings?
- TG Therapeutics (TGTX) reported retained earnings of -$1.05B in Q2 2026.
- How has TG Therapeutics's retained earnings changed year-over-year?
- TG Therapeutics's retained earnings increased by 29.5% year-over-year, from -$1.5B to -$1.05B.
- What is the long-term trend for TG Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), TG Therapeutics's retained earnings has grown at a 2.0% compound annual growth rate (CAGR), from -$980.6M to -$1.08B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about TG Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude